Will This Trend Cost Biotech Stock Investors Lots of Money?
Fox Business A new approach for how payers reimburse for drugs is gaining traction. Merck (NYSE: MRK) became the latest to jump on board. The drugmaker forged a pay-for-performance deal with Aetnafor diabetes drugs Januvia and Janumet. But could this trend wind ... |
October 30, 2016 at 04:34PM | money - Google News
Will This Trend Cost Biotech Stock Investors Lots of Money? - Fox Business
money - Google News
money - Google News | October 30, 2016 at 04:34PM | Will This Trend Cost Biotech Stock Investors Lots of Money? - Fox Business
Nenhum comentário:
Postar um comentário